Physician profile
Donna E Roth
NPI 1518964758
$5,303.58
in general payments reported to CMS, 2019-2025
25 companies · $29.93 in 2025
The $29.93 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $13.66 · 2021: $760 · 2022: $2,228 · 2023: $1,659 · 2024: $307 · 2025: $29.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,915 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,915.36 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,351.91 | 2019-2024 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $861.73 | 2019-2024 | Tremfya |
| Pfizer INC. | $331.27 | 2019-2023 | |
| Lilly USA, LLC | $296.06 | 2021-2023 | Olumiant, Taltz |
| Leo Pharma INC. | $276.87 | 2021-2023 | Adbry |
| Genentech USA, INC. | $239.94 | 2019-2023 | Erivedge |
| Sun Pharmaceutical Industries INC. | $212.88 | 2021-2024 | Blu-U, Odomzo, Winlevi |
| Amgen INC. | $207.26 | 2019-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $193.53 | 2022-2024 | Sotyktu |
| Ucb, INC. | $142.73 | 2019-2023 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $134.94 | 2021-2024 | |
| Genzyme Corporation | $128.57 | 2021-2024 | |
| Incyte Corporation | $120.47 | 2021-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $109.79 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $97.10 | 2022-2023 | Libtayo, Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $92.63 | 2019 | |
| Galderma Laboratories, L.P. | $91.49 | 2019-2024 | Aklief |
| Almirall LLC | $87.20 | 2021-2023 | Klisyri |
| Stemline Therapeutics INC. | $83.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.81 | 2022-2023 | Spevigo, Cyltezo |
| Epi Health, LLC | $54.06 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.63 | 2021-2022 | |
| Dermavant Sciences, INC. | $28.52 | 2023 | Vtama |
| Fresenius Kabi USA, LLC | $17.10 | 2023 | Idacio |
| Biofrontera INC. | $15.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.